Stella M. Robertson

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

AyuVis Research, Inc. engages in the provision of pharmaceutical services. The company was founded by Suchi Acharya and Gagan Acharya in 2014 and is headquartered in Fort Worth, TX.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.

Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.

AyuVis Research, Inc. engages in the provision of pharmaceutical services. The company was founded by Suchi Acharya and Gagan Acharya in 2014 and is headquartered in Fort Worth, TX.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

ONL Therapeutics, Inc. develops biopharmaceutical services. It protects and improves the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration. The company was founded by David Zacks and Jeffery Jamison in 2006 and is headquartered in Ann Arbor, MI.

Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.